m6A-centered Crosstalk Information

Mechanism of Crosstalk between m6A Modification and Epigenetic Regulation
Crosstalk ID
M6ACROT03366
 [1], [2]
Histone modification H3K27ac HDAC2 ALKBH5 Direct Inhibition m6A modification TP53 TP53 ALKBH5 Demethylation : m6A sites
m6A Modification:
m6A Regulator RNA demethylase ALKBH5 (ALKBH5) ERASER
 Regulator Info 
m6A Target Cellular tumor antigen p53 (TP53/p53)
 Targert Gene 
Epigenetic Regulation that have Cross-talk with This m6A Modification:
Epigenetic Regulation Type Histone modification (HistMod)
Epigenetic Regulator Histone deacetylase 2 (HDAC2) ERASER View Details
Regulated Target Histone H3 lysine 27 acetylation (H3K27ac) View Details
Downstream Gene ALKBH5 View Details
Crosstalk Relationship Histone modification  →  m6A Inhibition
Crosstalk Mechanism histone modification directly impacts m6A modification through modulating the level of m6A regulator
Crosstalk Summary Mechanically, HDAC2-reduced Histone H3 lysine 27 acetylation (H3K27ac) inhibits ALKBH5 transcription in CRC, whereas ectopic ALKBH5 expression decreases tumorigenesis of CRC cells and protects mice from colitis-associated tumor development.METTL14/ALKBH5/IGF2BPs combine to modulate JMJD8 stability in an m6A-dependent manner, which increases glycolysis and accelerates the development of CRC by enhancing the enzymatic activity of PKM2. The interplay between CARMN and ALKBH5 promoted tumourigenesis in colorectal cancer patients via the Cellular tumor antigen p53 (TP53/p53)/ALKBH5/CARMN/miR-5683 pathway. These findings illuminate the role of m6A methylation in colorectal cancer patients with p53R273H mutation.
Responsed Disease Colorectal cancer ICD-11: 2B91
 Disease Info 
In-vitro Model
 HIEC-6 Normal Homo sapiens CVCL_6C21
FHC Normal Homo sapiens CVCL_3688
HCT 116 Colon carcinoma Homo sapiens CVCL_0291
SW480 Colon adenocarcinoma Homo sapiens CVCL_0546
SW620 Colon adenocarcinoma Homo sapiens CVCL_0547
HT29 Colon cancer Mus musculus CVCL_A8EZ
In-vivo Model Colorectal cancer cells were seeded in culture plates for 24 h prior to cotransfection with GFP-CARMN, and a vector using Lipofectamine 2000. After 48 h, RNA immunoprecipitation was performed using/Colorectal cancer cells were plated in 24-well plates and incubated for 24 h before cotransfection with the luciferase reporter vector, and the Renilla vector. antibodies against FTO, METTL3 and ALKBH5 from the EZ-Magna RIP Kit (Millipore).
Full List of Potential Compound(s) Related to This m6A-centered Crosstalk
Cellular tumor antigen p53 (TP53/p53) 27 Compound(s) Regulating the Target Click to Show/Hide the Full List
 Compound Name Contusugene ladenovec Phase 3 [3]
Synonyms
Advexin; Ad5CMV-p53; INGN-004; INGN-201; Ad-p53, Introgen; Gene therapy (p53/adenovirus), University of Texas; Gene therapy (p53/adenoviral), Introgen/Aventis; Gene therapy (p53/adenoviral), Introgen/RPR
    Click to Show/Hide
MOA Modulator
External Link
TTD: D04FYL
 Compound Name QPI-1002 Phase 3 [4]
MOA Modulator
External Link
TTD: D0D5ZU
 Compound Name Thymoquinone Phase 2/3 [5]
Synonyms
490-91-5; Thymoquinon; p-Cymene-2,5-dione; 2-Isopropyl-5-methyl-1,4-benzoquinone; 2,5-CYCLOHEXADIENE-1,4-DIONE, 2-METHYL-5-(1-METHYLETHYL)-; 2-Isopropyl-5-methyl-p-benzoquinone; 2-Isopropyl-5-methylbenzoquinone; Polythymoquinone; 5-Isopropyl-2-methyl-1,4-benzoquinone; 2-Isopropyl-5-methylbenzo-1,4-quinone; p-Mentha-3,6-diene-2,5-dione; NSC 2228; 2-Isopropyl-5-methylcyclohexa-2,5-diene-1,4-dione; 2-Methyl-5-isopropyl-p-benzoquinone; 2-methyl-5-propan-2-ylcyclohexa-2,5-diene-1,4-dione; NSC2228; 2-methyl-5-(propan-2-yl)cyclohexa-2,5-diene-1,4-dione; UNII-O60IE26NUF; 2-Methyl-5-isopropyl-1,4-benzoquinone; O60IE26NUF; 2,5-Cyclohexadiene-1,4-dione, 5-isopropyl-2-methyl-; NSC-2228; 5-Isopropyl-2-methyl-p-benzoquinone; MFCD00001602; 2-Methyl-5-(1-methylethyl)-2,5-cyclohexadiene-1,4-dione; p-Mentha-3,6-diene-2,5-dione (8CI); 5-Isopropyl-2-methyl-2,5-Cyclohexadiene-1,4-dione; CCRIS 7152; EINECS 207-721-1; 2-methyl-5-(methylethyl)cyclohexa-2,5-diene-1,4-dione; BRN 1939047; thymolquinone; Thymoil; AI3-17758; 4hco; p-Mentha-3,5-dione; Spectrum_001237; SpecPlus_000457; Thymoquinone, >=98%; Spectrum2_000700; Spectrum3_001345; Spectrum4_001895; Spectrum5_000550; BSPBio_003129; KBioGR_002455; KBioSS_001717; DivK1c_006553; SCHEMBL542535; SPBio_000859; CHEMBL1672002; DTXSID9060079; KBio1_001497; KBio2_001717; KBio2_004285; KBio2_006853; KBio3_002349; Thymoquinone, analytical standard; CHEBI:113532; 2-Methyl-5-iso-propylbenzoquinone; BDBM166686; ZINC164367; BCP16946; HY-D0803; WLN: L6V DVJ B1 EY1&1; 2,4-dione, 5-isopropyl-2-methyl-; ANW-41600; CCG-40027; s4761; SBB008296; AKOS003368628; MCULE-9899033250; NCGC00178250-01; NCGC00178250-05; 73940-92-8; AK101679; AS-11327; 2-Isopropyl-5-methylbenzo-1,4-quinone #; 2,4-dione, 2-methyl-5-(1-methylethyl)-; CS-0012226; FT-0612708; ST45023960; K-9199; SR-05000002192; Q7799650; SR-05000002192-2; W-202869; BRD-K97566842-001-03-5; 2-methyl-5-(propan-2-yl)cyclohexa-2,5-diene-1,4-dione (F8); 2-Methyl-5-(1-methylethyl)-2,5-cyclohexadiene-1,4-dione, 9CI
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 10281
TTD: DY4OZ6
 Compound Name SGT-53 Phase 2 [6]
Synonyms
P53 gene stimulator (solid tumor), Synergene Therapeutics
    Click to Show/Hide
MOA Stimulator
External Link
TTD: D02EOH
 Compound Name APR-246 Phase 2 [7]
Synonyms
Eprenetapopt
    Click to Show/Hide
MOA Stimulator
External Link
CID: 52918385
TTD: D03XTY
DrugBank: DB11684
 Compound Name Ad-p53 Phase 2 [8]
Synonyms
P53 gene therapy, Transgene/Schering-Plough; Ad-p53, Transgene/Schering-Plough
    Click to Show/Hide
MOA Modulator
External Link
TTD: D0CO9B
 Compound Name Kevetrin Phase 2 [9]
MOA Stimulator
External Link
CID: 437740
TTD: D0K7DV
DrugBank: DB13010
 Compound Name INGN-225 Phase 2 [10]
Synonyms
Cancer vaccine (p53), Introgen
    Click to Show/Hide
External Link
TTD: D0V2SP
 Compound Name ALT-801 Phase 2 [11]
Synonyms
ALT-801 (donor lymphocyte infusion, cancer); ALT-801 (donor lymphocyte infusion, cancer), Altor; STAR IL-2 conjugate (donor lymphocyte infusion, cancer), Altor; STAR-Ck (donor lymphocyte infusion, cancer), Altor; Soluble T-cell Antigen Receptor IL-2 conjugate (donor lymphocyte infusion, cancer), Altor
    Click to Show/Hide
MOA Immunomodulator (Immunostimulant)
External Link
TTD: D0V5JH
 Compound Name APG-115 Phase 2 [9]
Synonyms
15Qau0SI9J; UNII-15QAU0SI9J; 1818393-16-6; APG 115 [WHO-DD]; SCHEMBL17189805; Bicyclo(2.2.2)octane-1-carboxylic acid, 4-((((3'R,4'S,5'R)-6''-chloro-4'-(3-chloro-2-fluorophenyl)-1'-ethyl-1'',2''-dihydro-2''-oxodispiro(cyclohexane-1,2'-pyrrolidine-3',3''-(3H)indol)-5'-yl)carbonyl)amino)-
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 91972012
TTD: D04SXL
 Compound Name ISA-P53-01 Phase 1/2 [12]
Synonyms
P53-SLP; P53 vaccine (colorectal/ovarian cancer), ISA Pharmaceuticals; P53 vaccine (Montanide ISA-51 adjuvanted, colorectal/ovarian cancer), ISA Pharmaceuticals
    Click to Show/Hide
External Link
TTD: D0KK4N
 Compound Name SAR-405838 Phase 1 [13]
Synonyms
AT-219; MI-147; MI-219; MI-319; MI-43; MI-5; MI-63; MI-772; MI-773; MI-519-64; P53-HDM2 protein interaction inhibitors (cancer); P53-HDM2 protein interaction inhibitors (cancer), Ascenta/Sanofi; P53-HDM2 protein interaction inhibitors (cancer), Ascenta/sanofi-aventis
    Click to Show/Hide
MOA Modulator
External Link
CID: 53476877
TTD: D03YSQ
DrugBank: DB12541
 Compound Name Dendritic cell vaccine Phase 1 [14]
Synonyms
Dendritic cell vaccine (injectable, head and neck cancer); Dendritic cell vaccine (injectable, head and neck cancer), National Cancer Institute; Mutant p53 peptide pulsed dendritic cell vaccine (injectable, head and neck cancer), National Cancer Institute
    Click to Show/Hide
External Link
TTD: D05CPS
 Compound Name ONYX-015 Phase 1 [15]
Synonyms
Dl1520; E1B-deleted adenovirus (cancer), ONYX
    Click to Show/Hide
MOA Modulator
External Link
TTD: D0G7YS
 Compound Name COTI-2 Phase 1 [9]
Synonyms
UNII-2BTA1O65BR; 2BTA1O65BR; 1039455-84-9; ZINC114475331; CS-8156; HY-19896; 1-Piperazinecarbothioic acid, 4-(2-pyridinyl)-, 2-(6,7-dihydro-8(5H)-quinolinylidene)hydrazide
    Click to Show/Hide
MOA Modulator
External Link
CID: 91810660
TTD: D0G8CU
 Compound Name CGM097 Phase 1 [4]
MOA Modulator
External Link
CID: 53240420
TTD: D0Q7AG
 Compound Name HDM201 Phase 1 [16]
MOA Inhibitor
External Link
CID: 71678098
TTD: D01KTG
 Compound Name INGN-234 Discontinued in Phase 2 [17]
Synonyms
P53 tumor suppressor (topical formulation), Introgen
    Click to Show/Hide
MOA Suppressor
External Link
TTD: D05AHK
 Compound Name Pifithrin-alpha Terminated [18]
Synonyms
P53 inhibitor, Univ of Illinois; PFT-alpha; PFT-beta; Pifithrin compounds, Quark; Pifithrin-beta
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 9929138
TTD: D02NYK
 Compound Name TAR-1 Terminated [19]
Synonyms
P53 protein modulator (single-chain antibody fragment, cancer), Ramot/Champions
    Click to Show/Hide
External Link
TTD: D0LG1K
 Compound Name 1-(9-ethyl-9H-carbazol-3-yl)-N-methylmethanamine Investigative [20]
Synonyms
PhiKan 083; [(9-ethyl-9H-carbazol-3-yl)methyl](methyl)amine; EN300-43214; 880813-36-5; AC1NGDXR; PhiKan-083; BAS 13152361; PhiKan-083 Hydrochloride; CHEMBL1235116; SCHEMBL20181195; AC1Q3123; ZINC3888893; STK511393; IMED102848735; AKOS000284549; MCULE-1841863738; DB08363; NCGC00379107-01; NCGC00379107-02; ST072505; [(9-ethylcarbazol-3-yl)methyl]methylamine; HY-108637; CS-0029368; [(9-ethylcarbazol-3-yl)methyl](methyl)amine; 1-(9-ethylcarbazol-3-yl)-N-methylmethanamine
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 4722579
TTD: D08PLU
DrugBank: DB08363
 Compound Name NUTLIN-3 Investigative [21]
Synonyms
548472-68-0; 890090-75-2; nutlin-3A; nutlin 3; (+/-)-Nutlin3; CHEMBL211045; Nutlin 3(Random Configuration); MDM2 Antagonist, Nutlin-3, Racemic; 4-(4,5-bis(4-chlorophenyl)-2-(2-isopropoxy-4-methoxyphenyl)-4,5-dihydro-1H-imidazole-1-carbonyl)piperazin-2-one; 4-({4,5-bis(4-chlorophenyl)-2-[4-methoxy-2-(propan-2-yloxy)phenyl]-4,5-dihydro-1H-imidazol-1-yl}carbonyl)piperazin-2-one; 4-[4,5-bis(4-chlorophenyl)-2-(4-methoxy-2-propan-2-yloxyphenyl)-4,5-dihydroimidazole-1-carbonyl]piperazin-2-one
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 216345
TTD: D01QKK
 Compound Name NU-8231 Investigative [22]
Synonyms
SCHEMBL2454464; CHEMBL360944
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 11648438
TTD: D0F1SN
 Compound Name OPI-1002 Phase 2 [23]
External Link
TTD: D02CKH
 Compound Name Cenersen Phase 2 [23]
External Link
CID: 56841947
TTD: D0K4VW
 Compound Name AHL Investigative [23]
Synonyms
AHLi-11; SiRNA therapeutics (hearing loss), Quark; P53 gene-silencing siRNA (hearing loss), Quark
    Click to Show/Hide
External Link
TTD: D0T8EL
 Compound Name PC14586 Phase 1/2 [23]
External Link
TTD: D53CGK
Histone deacetylase 2 (HDAC2) 113 Compound(s) Regulating the Target Click to Show/Hide the Full List
 Compound Name CHR-3996 Phase 1/2 [24]
Synonyms
CCT-075453; CHR-2504; HDAC inhibitors, Chroma Therapeutics; Histone deacetylase inhibitors, Chroma
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 4 nM
External Link
CID: 49857317
TTD: D06TKI
DrugBank: DB15419
 Compound Name PMID29671355-Compound-74 Patented [25]
MOA Inhibitor
Activity IC50 = 119 nM
External Link
CID: 72946782
TTD: D0N2FN
 Compound Name PMID29671355-Compound-59 Patented [25]
MOA Inhibitor
Activity IC50 = 10 nM
External Link
CID: 130319551
TTD: D0C9NX
 Compound Name PMID29671355-Compound-55 Patented [25]
MOA Inhibitor
Activity IC50 < 1000 nM
External Link
CID: 60198673
TTD: D0OU0J
 Compound Name PMID29671355-Compound-11 Patented [25]
MOA Inhibitor
Activity IC50 = 24 nM
External Link
CID: 118005782
TTD: D0EH2K
 Compound Name PMID29671355-Compound-9 Patented [25]
MOA Inhibitor
Activity IC50 = 128 nM
External Link
CID: 57381425
TTD: D0Q1QY
 Compound Name PMID29671355-Compound-8 Patented [25]
MOA Inhibitor
Activity IC50 = 123000 nM
External Link
TTD: D0LN1T
 Compound Name PMID29671355-Compound-61 Patented [25]
MOA Inhibitor
Activity IC50 = 45.9 nM
External Link
TTD: D0JB4S
 Compound Name PMID29671355-Compound-23 Patented [25]
MOA Inhibitor
Activity IC50 = 7450 nM
External Link
CID: 118884610
TTD: D00HXJ
 Compound Name PMID29671355-Compound-44 Patented [25]
MOA Inhibitor
Activity IC50 < 150 nM
External Link
CID: 72710871
TTD: D0N2DK
 Compound Name PMID29671355-Compound-56 Patented [25]
MOA Inhibitor
Activity IC50 = 54.4 nM
External Link
CID: 56965342
TTD: D0CH8Q
 Compound Name PMID29671355-Compound-67 Patented [25]
MOA Inhibitor
Activity IC50 > 50000 nM
External Link
CID: 60201048
TTD: D0M0RE
 Compound Name PMID29671355-Compound-31 Patented [25]
MOA Inhibitor
Activity IC50 = 2 nM
External Link
CID: 90479372
TTD: D0DI9S
DrugBank: DB14979
 Compound Name PMID29671355-Compound-21 Patented [25]
MOA Inhibitor
Activity IC50 = 4880 nM
External Link
CID: 86295624
TTD: D0LP1K
 Compound Name PMID29671355-Compound-62 Patented [25]
MOA Inhibitor
Activity IC50 = 100 to 500 nM
External Link
TTD: D07WAT
 Compound Name PMID29671355-Compound-43 Patented [25]
MOA Inhibitor
Activity IC50 = 124 nM
External Link
CID: 118515590
TTD: D0BP8I
 Compound Name PMID29671355-Compound-25 Patented [25]
MOA Inhibitor
Activity IC50 = 5400 nM
External Link
CID: 126569528
TTD: D0RA0D
 Compound Name N8-hydroxy-2-methoxy-N1-phenyloctanediamide Investigative [26]
Synonyms
CHEMBL251010; SCHEMBL8158442
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 500 nM
External Link
CID: 25065930
TTD: D01AVS
 Compound Name N-(4'-acetyl-4-aminobiphenyl-3-yl)benzamide Investigative [27]
Synonyms
CHEMBL1099078; BDBM50317997
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 3800 nM
External Link
CID: 46887380
TTD: D01TSM
 Compound Name N-Hydroxy-E-3-(4'-chlorobiphenyl-4-yl)-acrylamide Investigative [28]
Synonyms
CHEMBL557066; SCHEMBL3292989; SCHEMBL3292983; BDBM50293365
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 1860 nM
External Link
CID: 15986508
TTD: D02TQA
 Compound Name N7-hydroxy-2-methoxy-N1-phenylheptanediamide Investigative [26]
Synonyms
CHEMBL251206; SCHEMBL8143763
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 500 nM
External Link
CID: 25065710
TTD: D03TNE
 Compound Name N7-hydroxy-N1-phenyl-2-propoxyheptanediamide Investigative [26]
Synonyms
CHEMBL251406; SCHEMBL8144856
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 500 nM
External Link
CID: 25065713
TTD: D03TQD
 Compound Name N-(4-amino-4'-vinylbiphenyl-3-yl)benzamide Investigative [27]
Synonyms
CHEMBL1096397; BDBM50318002
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 800 nM
External Link
CID: 46887334
TTD: D05RWU
 Compound Name N-(4-amino-3'-methoxybiphenyl-3-yl)benzamide Investigative [27]
Synonyms
CHEMBL1097747; BDBM50317991
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 1300 nM
External Link
CID: 46887438
TTD: D06IWR
 Compound Name KAR-1880 Investigative [29]
Synonyms
Anti-inflammatory OS-HDI; OS-HDI-2; HDAC 2 inhibitors (topical, dermatitis/psoriasis), Karus
    Click to Show/Hide
MOA Inhibitor
External Link
TTD: D06YYY
 Compound Name N-(2-amino-5-(pyridin-4-yl)phenyl)benzamide Investigative [27]
Synonyms
CHEMBL1095096
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 3900 nM
External Link
CID: 46887378
TTD: D07BMT
 Compound Name N-(4-amino-3'-methylbiphenyl-3-yl)benzamide Investigative [27]
Synonyms
CHEMBL1094108; BDBM50317995
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 3100 nM
External Link
CID: 46887381
TTD: D07WSB
 Compound Name N-(3'-acetyl-4-aminobiphenyl-3-yl)benzamide Investigative [27]
Synonyms
CHEMBL1097746; BDBM50317992
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 13000 nM
External Link
CID: 46887437
TTD: D08USK
 Compound Name N-(4-amino-4'-fluorobiphenyl-3-yl)benzamide Investigative [27]
Synonyms
CHEMBL1098337; SCHEMBL15398027; BDBM50317988
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 1400 nM
External Link
CID: 46830345
TTD: D08YLO
 Compound Name N8,2-dihydroxy-N1-phenyloctanediamide Investigative [26]
Synonyms
CHEMBL251009; SCHEMBL8144564
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 500 nM
External Link
CID: 25065929
TTD: D09SVH
 Compound Name N-(2-amino-5-(furan-3-yl)phenyl)benzamide Investigative [27]
Synonyms
CHEMBL1095095; Benzamide, N-[2-amino-5-(3-furanyl)phenyl]-; BDBM50318000
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 39 nM
External Link
CID: 46830327
TTD: D0A4KW
 Compound Name N-Hydroxy-E-3-(biphenyl-4-yl)-acrylamide Investigative [28]
Synonyms
CHEMBL556532; SCHEMBL3292226; SCHEMBL3290139
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 820 nM
External Link
CID: 42632368
TTD: D0AK8Q
 Compound Name 2-(allyloxy)-N8-hydroxy-N1-phenyloctanediamide Investigative [26]
Synonyms
CHEMBL402719; SCHEMBL8150833
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 500 nM
External Link
CID: 25065931
TTD: D0D2US
 Compound Name 2-(benzyloxy)-N7-hydroxy-N1-phenylheptanediamide Investigative [26]
Synonyms
CHEMBL402718; SCHEMBL8152458
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 500 nM
External Link
CID: 25065925
TTD: D0FI2F
 Compound Name N-(4-amino-4'-bromobiphenyl-3-yl)benzamide Investigative [27]
Synonyms
CHEMBL1097748; BDBM50317990
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 600 nM
External Link
CID: 46887439
TTD: D0H4SC
 Compound Name N-(2-amino-5-(furan-2-yl)phenyl)benzamide Investigative [27]
Synonyms
CHEMBL1097651
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 43 nM
External Link
CID: 46830328
TTD: D0I2KC
 Compound Name 5-(Biphenyl-4-yl)-pentanoic acid N-hydroxyamide Investigative [28]
Synonyms
CHEMBL541239; SCHEMBL7045815
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 720 nM
External Link
CID: 22915475
TTD: D0K3MR
 Compound Name N-(4-aminobiphenyl-3-yl)benzamide Investigative [27]
Synonyms
CHEMBL271741; 3max; SCHEMBL16380794; BDBM50232053; N-(4-amino-biphenyl-3-yl)-benzamide
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 27 nM
External Link
CID: 44454143
TTD: D0MD7H
 Compound Name N-(2-amino-5-(benzofuran-2-yl)phenyl)benzamide Investigative [27]
Synonyms
CHEMBL1097063
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 10000 nM
External Link
CID: 46887475
TTD: D0Q4LX
 Compound Name N-(2-aminophenyl)benzamide Investigative [27]
Synonyms
2'-AMINOBENZANILIDE; 721-47-1; CHEMBL405072; AC1LFSYX; AC1Q5NOK; ACMC-1AE0C; Oprea1_478192; MLS000084661; SCHEMBL407834; N-(2-amino-phenyl)-benzamide; AC1Q514U; Benzamide, N-(2-aminophenyl)-; CTK2H2825; DTXSID60353948; RFDVMOUXHKTCDO-UHFFFAOYSA-N; MolPort-001-783-352; ZINC225957; HMS2355D18; STL497474; BDBM50232046; AKOS000133162; MCULE-5545982713; NE17312; SMR000019009; TC-170926; KB-298435; ST51030142; EN300-31745; SR-01000389415; AE-641/00785046
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 3100 nM
External Link
CID: 759408
TTD: D0U8FC
 Compound Name N-(4-amino-4'-methoxybiphenyl-3-yl)benzamide Investigative [27]
Synonyms
CHEMBL1095412; BDBM50317998
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 140 nM
External Link
CID: 46887379
TTD: D0W2PX
 Compound Name N-Hydroxy-E-3-(4'-cyanobiphenyl-4-yl)-acrylamide Investigative [28]
Synonyms
CHEMBL538710; SCHEMBL3292721; SCHEMBL3292715; BDBM50293355
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 330 nM
External Link
CID: 15986510
TTD: D0W9BH
 Compound Name N-(2-amino-5-(thiazol-2-yl)phenyl)benzamide Investigative [27]
Synonyms
CHEMBL1097278
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 390 nM
External Link
CID: 46887333
TTD: D0Y4SD
 Compound Name N-(2-aminophenyl)quinoxaline-6-carboxamide Investigative [30]
Synonyms
benzamide-type inhibitor, 20; CHEMBL236060; BDBM19424
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 2000 nM
External Link
CID: 23648267
TTD: D01FYB
 Compound Name 7-Biphenyl-4-yl-heptanoic acid hydroxyamide Investigative [31]
Synonyms
CHEMBL125098; BDBM50222335; 7-(4-Biphenylyl)heptanehydroximic acid
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 44349481
TTD: D01RJY
 Compound Name 8-(Biphenyl-4-yloxy)-2-oxo-octanoic acid Investigative [32]
Synonyms
CHEMBL115049; 436150-72-0; SCHEMBL7368556; CTK1D2674; DTXSID40658342; BDBM50221807; 8-[([1,1'-Biphenyl]-4-yl)oxy]-2-oxooctanoic acid; Octanoic acid, 8-([1,1'-biphenyl]-4-yloxy)-2-oxo-
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 44341224
TTD: D03XXI
 Compound Name 1,1,1-Trifluoro-8-phenoxy-octan-2-one Investigative [33]
Synonyms
CHEMBL114796; BDBM50217940
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 44342886
TTD: D04ETX
 Compound Name 7-(Biphenyl-4-yloxy)-heptanoic acid hydroxyamide Investigative [32]
Synonyms
CHEMBL114184; SCHEMBL3383144
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 22915465
TTD: D04LLD
 Compound Name 7-Phenoxy-heptanoic acid hydroxyamide Investigative [31]
Synonyms
CHEMBL124322; N-hydroxy-7-phenoxyheptanamide; 7-Phenoxyheptanehydroximic acid
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 25798548
TTD: D05ZGM
 Compound Name 1,1,1-Trifluoro-8-(4-phenoxy-phenoxy)-octan-2-one Investigative [33]
Synonyms
CHEMBL117916; SCHEMBL7366611; BDBM50217945
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 44342905
TTD: D06BKA
 Compound Name N-(4-hydroxybiphenyl-3-yl)benzamide Investigative [34]
Synonyms
CHEMBL269935; SCHEMBL5724398; BDBM50232005
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 200 nM
External Link
CID: 44454650
TTD: D0E0TA
 Compound Name 8-Phenyl-octanoic acid hydroxyamide Investigative [31]
Synonyms
CHEMBL123624; N-Hydroxy-8-phenyloctanamide; SCHEMBL5807174
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 14098189
TTD: D0H9DS
 Compound Name 8-(Biphenyl-3-yloxy)-1,1,1-trifluoro-octan-2-one Investigative [33]
Synonyms
CHEMBL116023; SCHEMBL7368359; BDBM50218558
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 44343094
TTD: D0NL6C
 Compound Name N-(2-aminophenyl)nicotinamide Investigative [34]
Synonyms
N-(2-Amino-phenyl)-nicotinamide; 436089-31-5; N-(2-aminophenyl)pyridine-3-carboxamide; CHEMBL236678; AC1LMN6K; SCHEMBL18086514; CTK4I7538; DTXSID50360661; CHEBI:125506; ZINC873967; BDBM50220259; 3463AE; AKOS000129725; RTR-042156; MCULE-7933541910; N-(2-aminophenyl)-3-pyridylcarboxamide; ZB014940; ACM436089315; ST086607; ASN 01337807; KB-298440; TR-042156; BC4148434; SR-01000329900; SR-01000329900-1; BRD-K20880473-001-04-6
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 6980 nM
External Link
CID: 1133083
TTD: D04UVL
 Compound Name santacruzamate A Investigative [35]
Synonyms
CAY10683
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 0.112 nM
External Link
CID: 72946782
TTD: D09RKA
 Compound Name N-(4-aminobiphenyl-3-yl)nicotinamide Investigative [34]
Synonyms
CHEMBL255805; BDBM50232035
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 900 nM
External Link
CID: 44454415
TTD: D0M9LJ
 Compound Name N-(2-amino-5-(thiophen-2-yl)phenyl)nicotinamide Investigative [34]
Synonyms
CHEMBL256440; SCHEMBL1066609
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 390 nM
External Link
CID: 44454416
TTD: D0Q2GM
 Compound Name N-(2-aminophenyl)-4-methoxybenzamide Investigative [30]
Synonyms
AC1LFX2W; Cambridge id 5129152; Oprea1_722128; benzamide-type inhibitor, 22; CHEMBL236061; SCHEMBL5226034; BDBM19426; CTK7A1998; MolPort-001-019-504; BDYVCYUXCNZYRW-UHFFFAOYSA-N; ZINC281656; STK156256; AKOS000130378; MCULE-9183453747; N-(2-Amino-phenyl)4-methoxy-benzamide; N-(2-amino-phenyl)-4-methoxy-benzamide; NCGC00240897-01; N1-(4-methoxybenzoyl)-1,2-benzenediamine; N1-(4-methoxy-benzoyl)-1,2-benzenediamine; ST50908739; N-(2-aminophenyl)(4-methoxyphenyl)carboxamide; SR-01000196394
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 900 nM
External Link
CID: 785232
TTD: D0YO6M
 Compound Name 4-Phenylbutyrohydroxamic acid Investigative [36]
Synonyms
N-Hydroxy-4-phenylbutanamide; 32153-46-1; NSC131300; UNII-QX182FOM5S; QX182FOM5S; 4-phenylbutanehydroxamic acid; CHEMBL55895; Benzenebutanamide, N-hydroxy-; NSC 131300; AC1Q7DIW; AC1L5RDX; Phenylbutyrylhydroxamic Acid; AC1Q5QD1; N-Hydroxy-4-phenyl-butyramide; 4-Phenylbutyryl hydroxamic acid; SCHEMBL1350853; CTK4G8310; DTXSID60185943; MolPort-011-492-164; UPHXPXYRKPCXHK-UHFFFAOYSA-N; ZINC4962622; STL301752; BDBM50015142; AKOS009266186; MCULE-9765156954; NSC-131300; NE28489; BCB03_000829; EN300-68596
    Click to Show/Hide
MOA Inhibitor
Activity Ki = 430 nM
External Link
CID: 279980
TTD: D02NWS
 Compound Name 8-Oxo-8-phenyl-octanoic acid hydroxyamide Investigative [37]
Synonyms
CHEMBL95959; SCHEMBL3383197; N-hydroxy-8-oxo-8-phenyloctanamide
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 11075845
TTD: D0S0WK
 Compound Name Octanedioic acid bis-hydroxyamide Investigative [38]
Synonyms
Suberohydroxamic acid
    Click to Show/Hide
MOA Inhibitor
Activity Ki = 29 nM
External Link
CID: 5173
TTD: D07YZZ
 Compound Name ST-2986 Investigative [39]
Synonyms
CHEMBL471041; SCHEMBL3444455; BDBM50278219
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 11000 nM
External Link
CID: 44138031
TTD: D0N9AK
 Compound Name 9,9,9-Trifluoro-8-oxo-nonanoic acid phenylamide Investigative [33]
Synonyms
9,9,9-Trifluoro-8-Oxo-N-Phenylnonanamide; CHEMBL113537; 2gh6; SCHEMBL2702892; KRCXZGYVOZSCSF-UHFFFAOYSA-N; BDBM50121062; DB07553
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 1400 nM
External Link
CID: 9882812
TTD: D00KFF
DrugBank: DB07553
 Compound Name 7-Mercapto-heptanoic acid phenylamide Investigative [40]
Synonyms
Thiol-SAHA (t-SAHA); CHEMBL325676; SCHEMBL14821761; BDBM152692
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 1300 nM
External Link
CID: 11379392
TTD: D00SEE
 Compound Name 6-benzenesulfinylhexanoic acid hydroxamide Investigative [41]
Synonyms
6-(benzenesulfinyl)hexanoic acid hydroxyamide; 875737-03-4
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 11694528
TTD: D00ZSD
 Compound Name N-(2-Mercapto-ethyl)-N'-phenyl-succinamide Investigative [42]
Synonyms
CHEMBL193959
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 44401339
TTD: D01MFV
 Compound Name 7-Mercapto-heptanoic acid biphenyl-4-ylamide Investigative [40]
Synonyms
CHEMBL112311
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 11220728
TTD: D01XWZ
 Compound Name N-Hydroxy-4-phenylacetylamino-benzamide Investigative [43]
Synonyms
CHEMBL356824; 656261-23-3; SCHEMBL675578; CTK1J6158; DTXSID40458440; ZINC13533297; AKOS030583151; Benzeneacetamide, N-[4-[(hydroxyamino)carbonyl]phenyl]-
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 11196500
TTD: D01XXN
 Compound Name 6-(2-Bromo-acetylamino)-hexanoic acid phenylamide Investigative [40]
Synonyms
CHEMBL344920; 651767-99-6; SCHEMBL3736839; CTK1J8444; DTXSID50432973; HWYLREOMBVUGJQ-UHFFFAOYSA-N; BDBM50222416; ZINC13587789; AKOS030603042; N-Phenyl-6-(bromoacetylamino)hexanamide; Hexanamide, 6-[(bromoacetyl)amino]-N-phenyl-
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 9927379
TTD: D02MQM
 Compound Name N-Hydroxy-4-(phenylacetylamino-methyl)-benzamide Investigative [44]
Synonyms
CHEMBL143674; SCHEMBL673760
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 11323577
TTD: D02UTC
 Compound Name 7-(Biphenyl-4-yloxy)-1-oxazol-2-yl-heptan-1-one Investigative [45]
Synonyms
CHEMBL126355; BDBM50222394
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 44350626
TTD: D02WZK
 Compound Name Octanedioic acid hydroxyamide pyridin-4-ylamide Investigative [46]
Synonyms
SCHEMBL8082656; CHEMBL165162; ZINC13472304
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 10967421
TTD: D04GGW
 Compound Name N-(6-Mercapto-hexyl)-benzamide Investigative [40]
Synonyms
CHEMBL112364; BDBM50223650
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 11447748
TTD: D04HSS
 Compound Name 4-Hydroxy-N-(5-hydroxycarbamoyl-pentyl)-benzamide Investigative [46]
Synonyms
CHEMBL167455
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 11086699
TTD: D04NSP
 Compound Name N-Hydroxy-4-((R)-2-phenyl-butyrylamino)-benzamide Investigative [43]
Synonyms
SCHEMBL675474
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 11231829
TTD: D04ZDI
 Compound Name 6-benzenesulfonylhexanoic acid hydroxamide Investigative [41]
Synonyms
CHEMBL203207
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 11572583
TTD: D05AHZ
 Compound Name 9-(Biphenyl-4-yloxy)-1,1,1-trifluoro-nonan-2-one Investigative [33]
Synonyms
SCHEMBL7373122; CHEMBL116578
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 44342872
TTD: D05FEJ
 Compound Name Thioacetic acid S-(6-phenylcarbamoyl-hexyl) ester Investigative [40]
Synonyms
CHEMBL111806; SCHEMBL14812153
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 11254470
TTD: D05GVY
 Compound Name 4-Butyrylamino-N-hydroxy-benzamide Investigative [44]
Synonyms
CHEMBL142254; 656261-22-2; Benzamide, N-hydroxy-4-[(1-oxobutyl)amino]-; SCHEMBL675234; CTK1J6159; DTXSID90461262
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 11287488
TTD: D05LLX
 Compound Name 7-(Naphthalen-2-yloxy)-1-oxazol-2-yl-heptan-1-one Investigative [45]
Synonyms
CHEMBL127328
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 44350703
TTD: D05VFP
 Compound Name 7-Mercapto-heptanoic acid biphenyl-3-ylamide Investigative [40]
Synonyms
CHEMBL320323
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 11449823
TTD: D05XAN
 Compound Name 5-(4-hydroxyphenyl)-3H-1,2-dithiole-3-thione Investigative [47]
MOA Inhibitor
External Link
CID: 3082127
TTD: D06IQB
 Compound Name N-Hydroxy-4-(2-phenyl-butyrylamino)-benzamide Investigative [43]
Synonyms
SCHEMBL676079
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 11347053
TTD: D06VBN
 Compound Name 4-Dimethylamino-N-(6-mercapto-hexyl)-benzamide Investigative [40]
Synonyms
CHEMBL324126
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 11277483
TTD: D06XNP
 Compound Name 7-Mercapto-heptanoic acid pyridin-3-ylamide Investigative [40]
Synonyms
CHEMBL332246; Heptanamide, 7-mercapto-N-3-pyridinyl-; BDBM50223653
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 11345433
TTD: D07FJU
 Compound Name 6-Phenoxy-hexane-1-thiol Investigative [40]
Synonyms
CHEMBL109796; 6-phenoxyhexane-1-thiol; 1-Hexanethiol, 6-phenoxy-; SCHEMBL5679745; MolPort-020-180-823; BDBM50223652; AKOS018584222; MCULE-9521857089
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 11298778
TTD: D09YBN
 Compound Name 4-Benzoylamino-N-hydroxy-benzamide Investigative [43]
Synonyms
SCHEMBL673678; CHEMBL191227
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 11817702
TTD: D09ZNU
 Compound Name 4-Chloro-N-(5-hydroxycarbamoyl-pentyl)-benzamide Investigative [37]
Synonyms
CHEMBL143734; NSC718168; AC1L8L82; SCHEMBL13039735; ZINC5579677; BDBM50082664; NSC-718168; NCI60_040737; 6-(4-Chlorobenzoylamino)hexanehydroxamic acid
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 403373
TTD: D0A5LS
 Compound Name 8-(Biphenyl-4-yloxy)-1,1,1-trifluoro-octan-2-one Investigative [33]
Synonyms
CHEMBL112148; SCHEMBL7364383; BDBM50218532
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 44341053
TTD: D0AX7B
 Compound Name 7-(Biphenyl-3-yloxy)-1-oxazol-2-yl-heptan-1-one Investigative [45]
Synonyms
CHEMBL127351; SCHEMBL7365180; HWZHDGRMABBYOV-UHFFFAOYSA-N; BDBM50222367; 7-((1,1'-biphenyl)-3-yloxy)-1-(1 ,3-oxazol-2-yl)-1-heptanone
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 44350718
TTD: D0B2ZJ
 Compound Name 6-Mercapto-hexanoic acid phenylamide Investigative [40]
Synonyms
CHEMBL109654; Hexanamide, 6-mercapto-N-phenyl-; SCHEMBL14254925; BDBM50027600
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 2220 nM
External Link
CID: 11436024
TTD: D0B3ZM
 Compound Name Cyclostellettamine derivative Investigative [48]
Synonyms
CHEMBL88332
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 23327627
TTD: D0C0VP
 Compound Name N-(5-Hydroxycarbamoyl-pentyl)-4-nitro-benzamide Investigative [37]
Synonyms
CHEMBL139999; SCHEMBL1232700; BDBM50082661; ZINC13472309
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 9943996
TTD: D0C2KD
 Compound Name 5-Mercapto-pentanoic acid phenylamide Investigative [40]
Synonyms
N-Phenyl-5-mercaptovaleramide; CHEMBL114344; Pentanamide, 5-mercapto-N-phenyl-
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 11608171
TTD: D0D2KE
 Compound Name Octanedioic acid hydroxyamide pyridin-2-ylamide Investigative [46]
Synonyms
SCHEMBL8090513; CHEMBL164872; ZINC13472303
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 11747496
TTD: D0E8KR
 Compound Name N-(2-Mercapto-ethyl)-N'-phenyl-oxalamide Investigative [42]
Synonyms
CHEMBL193979
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 44401305
TTD: D0F0KS
 Compound Name 2-(methylsulfonylthio)ethyl 2-propylpentanoate Investigative [47]
Synonyms
CHEMBL271677; SCHEMBL4156413
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 24759251
TTD: D0H1FZ
 Compound Name (E)-8-Biphenyl-4-yl-1-oxazol-2-yl-oct-7-en-1-one Investigative [45]
Synonyms
CHEMBL126465; SCHEMBL7368197; SCHEMBL7368201
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 44350655
TTD: D0KE3I
 Compound Name N-Hydroxy-4-((S)-2-phenyl-butyrylamino)-benzamide Investigative [43]
Synonyms
SCHEMBL676080
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 11312563
TTD: D0QO0L
 Compound Name N-Hydroxy-4-(3-phenyl-propionylamino)-benzamide Investigative [49]
Synonyms
N-hydroxy-4-(3-phenylpropanamido)benzamide
    Click to Show/Hide
MOA Inhibitor
External Link
TTD: D0R4BS
 Compound Name N-Hydroxy-4-(5-phenyl-pentanoylamino)-benzamide Investigative [43]
Synonyms
SCHEMBL7311087
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 11472431
TTD: D0R5VG
 Compound Name 8-Oxo-8-phenyl-octanoic acid Investigative [46]
Synonyms
8-Oxo-8-phenyloctanoic acid; 7-Benzoylheptanoic acid; 24314-23-6; Benzeneoctanoic acid, h-oxo-; 7-BENZOYL HEPTANOIC ACID; AC1L6TSB; SCHEMBL3381106; 8-keto-8-phenyl-caprylic acid; CHEMBL162423; 8-Oxo-8-phenyloctanoic acid #; CTK4F3363; DTXSID40305602; UMCSRRHQLAVYRS-UHFFFAOYSA-N; ZINC2168376; 7009f; NSC171230; AKOS016022495; NSC-171230; MCULE-7202530747; ACM24314236; ST50825837
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 298878
TTD: D0RU1X
 Compound Name N-Hydroxy-4-(4-phenyl-butyrylamino)-benzamide Investigative [43]
Synonyms
CHEMBL143336; 656261-24-4; SCHEMBL674421; CTK1J6157; DTXSID30433908; ZINC13533300; AKOS030583673; n-hydroxy-4-(4-phenylbutyryl-amino)benzamide; Benzenebutanamide, N-[4-[(hydroxyamino)carbonyl]phenyl]-
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 9994848
TTD: D0S7WQ
 Compound Name 6-phenylsulfanylhexanoic acid hydroxamide Investigative [41]
Synonyms
Hexanamide, N-hydroxy-6-(phenylthio)-; CHEMBL203028; SCHEMBL7317658
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 11637291
TTD: D0S9JF
 Compound Name ST-2987 Investigative [39]
Synonyms
CHEMBL471042; SCHEMBL3444989; SCHEMBL3444984; BDBM50278220
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 2670 nM
External Link
CID: 44138032
TTD: D0T0SK
 Compound Name 7-Mercapto-heptanoic acid quinolin-3-ylamide Investigative [40]
Synonyms
CHEMBL112234
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 10379373
TTD: D0T4IY
 Compound Name 5-(4-Chloro-phenyl)-pentanoic acid hydroxyamide Investigative [50]
Synonyms
CHEMBL84288
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 11528707
TTD: D0V2ZO
 Compound Name 8-Mercapto-octanoic acid phenylamide Investigative [40]
Synonyms
8-mercapto-N-phenyloctanamide; CHEMBL326433; ZINC13609343
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 754 nM
External Link
CID: 11149404
TTD: D0XZ9Q
 Compound Name N-(6-Hydroxycarbamoyl-hexyl)-benzamide Investigative [46]
Synonyms
CHEMBL57107; 174664-71-2; SCHEMBL573254; CTK0A7470; DTXSID00433435; BDBM50220823; ZINC13490043; 7-(Benzoylamino)heptanehydroxamic acid; AKOS030580013; Benzamide, N-[7-(hydroxyamino)-7-oxoheptyl]-
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 9965141
TTD: D0YY9M
 Compound Name 7-(Biphenyl-4-yloxy)-1,1,1-trifluoro-heptan-2-one Investigative [33]
Synonyms
CHEMBL326529; SCHEMBL7365237; BDBM50217957
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 44342825
TTD: D0Z3BM
 Compound Name 7-Mercapto-heptanoic acid benzothiazol-2-ylamide Investigative [40]
Synonyms
CHEMBL178779
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 11346934
TTD: D0Z5KX
 Compound Name N-Hydroxy-4-(pentanoylamino-methyl)-benzamide Investigative [44]
Synonyms
CHEMBL143102
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 44361923
TTD: D0Z7YS
 Compound Name PSAMMAPLIN A Investigative [37]
Synonyms
110659-91-1; Bisprasin; NSC614495; AC1O46WI; SCHEMBL364511; ZINC150352860; NSC-614495; B723735K022; J-002461; Benzenepropanamide, N,N'-(dithiodi-2,1-ethanediyl)bis(3-bromo-4-hydroxy-alpha-(hydroxyimino)-
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 6400741
TTD: D0N0TS
2B91: Colorectal cancer 25 Compound(s) Regulating the Disease Click to Show/Hide the Full List
 Compound Name Retifanlimab Approved [51]
Synonyms
INCMGA0012; Retifanlimab
    Click to Show/Hide
External Link
TTD: D0PG5O
 Compound Name Aflibercept Approved [52]
Synonyms
Ziv-Aflibercept; Zaltrap (TN); VEGF Trap; VEGF Trap-Eye
    Click to Show/Hide
External Link
TTD: D0C9ET
 Compound Name Regorafenib Approved [53]
Synonyms
755037-03-7; BAY 73-4506; Regorafenibum; Stivarga; 4-(4-(3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido)-3-fluorophenoxy)-N-methylpicolinamide; BAY73-4506; Regorafenib (BAY 73-4506); UNII-24T2A1DOYB; 4-[4-({[4-Chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide; BAY-73-4506; 24T2A1DOYB; CHEMBL1946170; CHEBI:68647; Stivarga (TN); BAY73-4506 hydrochloride; Regorafenib [USAN:INN]
    Click to Show/Hide
External Link
CID: 11167602
TTD: D09GDD
DrugBank: DB08896
 Compound Name Bevacizumab Approved [9]
Synonyms
Bevacizumab (ophthalmic slow-release tissue tablet)
    Click to Show/Hide
External Link
TTD: D04KBL
 Compound Name SYM-004 Phase 3 [9]
Synonyms
Chimeric IgG1 antibody 1024 (cancer), Symphogen; Chimeric IgG1 antibody 992 (cancer), Symphogen; Chimeric IgG1 antibodies992 + 1024 (cancer), Symphogen
    Click to Show/Hide
External Link
TTD: D0CR8H
 Compound Name Bevacizumab + Erlotinib Phase 3 [54]
External Link
TTD: D09BKY
 Compound Name CPI-613 Phase 3 [9]
Synonyms
95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874
    Click to Show/Hide
External Link
CID: 24770514
TTD: D07NVI
DrugBank: DB12109
 Compound Name Bevacizumab Approved [52]
External Link
TTD: D0FX3U
 Compound Name AlloStim Phase 2/3 [55]
Synonyms
AlloStim (TN)
    Click to Show/Hide
External Link
TTD: D0B3CC
 Compound Name Sibrotuzumab Phase 2 [56]
External Link
TTD: DVX3H0
 Compound Name CV301 Phase 2 [57]
External Link
TTD: D9LT5G
 Compound Name Efatutazone Phase 2 [58]
Synonyms
Inolitazone; 223132-37-4; 5-[[4-[[6-(4-amino-3,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-yl]methoxy]phenyl]methyl]-2,4-Thiazolidinedione; Efatutazone [INN]; RS5444; CS-7017; SCHEMBL3246054; CHEMBL3545280; JCYNMRJCUYVDBC-UHFFFAOYSA-N; Efatutazone;CS-7017;RS5444; BCP07478; AKOS030526729; DB11894; CS-0778; KB-77905; DA-07988; HY-14792; QC-10456; 4CA-1384; FT-0737589; 5-[4-[6-(4-amino-3 ,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-ylmethoxy]benzyl]thiazolidine-2,4-dione
    Click to Show/Hide
External Link
CID: 9832447
TTD: D0Y8NZ
DrugBank: DB11894
 Compound Name LOR-2040 Phase 2 [59]
External Link
TTD: D0I7NG
 Compound Name RG7221 Phase 2 [60]
External Link
TTD: D06FTM
 Compound Name PEG-SN38 Phase 2 [61]
Synonyms
EZN-2208
    Click to Show/Hide
External Link
CID: 59443782
TTD: D05UFP
 Compound Name MEGF0444A Phase 2 [62]
External Link
TTD: D01LES
 Compound Name Encapsulated cell therapy Phase 1/2 [63]
External Link
TTD: D0XY8C
 Compound Name AB928 Phase 1/2 [64]
External Link
CID: 135242184
TTD: D04UBI
 Compound Name MGD007 Phase 1 [60]
External Link
TTD: D00PEN
 Compound Name BNC-101 Phase 1 [65]
External Link
TTD: DD6AZ5
 Compound Name Navicixizumab Phase 1 [9]
External Link
TTD: D00IVN
 Compound Name RG7160 Discontinued in Phase 2 [66]
External Link
TTD: D0E2CQ
 Compound Name Nimesulide Terminated [67]
Synonyms
51803-78-2; N-(4-Nitro-2-phenoxyphenyl)methanesulfonamide; Mesulid; Flogovital; Sulidene; Nimed; R-805; 4-NITRO-2-PHENOXYMETHANESULFONANILIDE; Nisulid; Nimesulidum [INN-Latin]; Nimesulida [INN-Spanish]; R 805; UNII-V4TKW1454M; 4-Nitro-2-phenoxy-methanesulfonanilide; 4'-Nitro-2'-phenoxymethanesulfonanilide; Methanesulfonamide, N-(4-nitro-2-phenoxyphenyl)-; EINECS 257-431-4; 4'-Nitro-2'-phenoxymethansulfonanilid; BRN 2421175; CHEMBL56367; MLS000069680; V4TKW1454M; Methanesulfonanilide, 4'-nitro-2'-phenoxy-; CHEBI:44445; Dulanermin
    Click to Show/Hide
External Link
CID: 4495
TTD: D0C0JT
DrugBank: DB04743
 Compound Name Saracatinib Phase 2 [68]
External Link
CID: 10302451
TTD: D05YTN
DrugBank: DB11805
 Compound Name G3139 + Irinotecan Investigative [69]
External Link
CID: 91865905
TTD: D05IAN
References
Ref 1 Therapeutic m(6)A Eraser ALKBH5 mRNA-Loaded Exosome-Liposome Hybrid Nanoparticles Inhibit Progression of Colorectal Cancer in Preclinical Tumor Models. ACS Nano. 2023 Jun 27;17(12):11838-11854. doi: 10.1021/acsnano.3c03050. Epub 2023 Jun 13.
Ref 2 LncRNA CARMN m6A demethylation by ALKBH5 inhibits mutant p53-driven tumour progression through miR-5683/FGF2. Clin Transl Med. 2024 Jul;14(7):e1777. doi: 10.1002/ctm2.1777.
Ref 3 A review of contusugene ladenovec (Advexin) p53 therapy. Curr Opin Mol Ther. 2009 Feb;11(1):54-61.
Ref 4 Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics. 2005 Aug;86(2):127-41. doi: 10.1016/j.ygeno.2005.04.008.
Ref 5 Apoptosis as a mechanism for the treatment of adult T cell leukemia: promising drugs from benchside to bedside. Drug Discov Today. 2020 Jul;25(7):1189-1197. doi: 10.1016/j.drudis.2020.04.023. Epub 2020 May 7.
Ref 6 Transferrin receptor targeting nanomedicine delivering wild-type p53 gene sensitizes pancreatic cancer to gemcitabine therapy. Cancer Gene Ther. 2013 Apr;20(4):222-8. doi: 10.1038/cgt.2013.9. Epub 2013 Mar 8.
Ref 7 APR-246/PRIMA-1MET inhibits thioredoxin reductase 1 and converts the enzyme to a dedicated NADPH oxidase. Cell Death Dis. 2013 Oct 24;4(10):e881. doi: 10.1038/cddis.2013.417.
Ref 8 Assessment of p53 gene transfer and biological activities in a clinical study of adenovirus-p53 gene therapy for recurrent ovarian cancer. Cancer Gene Ther. 2003 Mar;10(3):224-38. doi: 10.1038/sj.cgt.7700562.
Ref 9 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
Ref 10 INGN-225: a dendritic cell-based p53 vaccine (Ad.p53-DC) in small cell lung cancer: observed association between immune response and enhanced chemotherapy effect. Expert Opin Biol Ther. 2010 Jun;10(6):983-91. doi: 10.1517/14712598.2010.484801.
Ref 11 Phase I trial of ALT-801, an interleukin-2/T-cell receptor fusion protein targeting p53 (aa264-272)/HLA-A*0201 complex, in patients with advanced malignancies. Clin Cancer Res. 2011 Dec 15;17(24):7765-75. doi: 10.1158/1078-0432.CCR-11-1817. Epub 2011 Oct 12.
Ref 12 WO patent application no. 2013,1850,32, Nanotherapeutics for drug targeting.
Ref 13 SAR405838: an optimized inhibitor of MDM2-p53 interaction that induces complete and durable tumor regression. Cancer Res. 2014 Oct 15;74(20):5855-65. doi: 10.1158/0008-5472.CAN-14-0799. Epub 2014 Aug 21.
Ref 14 Vaccination with p53-peptide-pulsed dendritic cells, of patients with advanced breast cancer: report from a phase I study. Cancer Immunol Immunother. 2004 Jul;53(7):633-41. doi: 10.1007/s00262-003-0493-5. Epub 2004 Feb 25.
Ref 15 Late viral RNA export, rather than p53 inactivation, determines ONYX-015 tumor selectivity. Cancer Cell. 2004 Dec;6(6):611-23. doi: 10.1016/j.ccr.2004.11.012.
Ref 16 National Cancer Institute Drug Dictionary (drug id 761551).
Ref 17 Prevent Oral Cancer With Mouthwash. Introgen Therapeutics.
Ref 18 An evaluation of the ability of pifithrin-alpha and -beta to inhibit p53 function in two wild-type p53 human tumor cell lines. Mol Cancer Ther. 2005 Sep;4(9):1369-77. doi: 10.1158/1535-7163.MCT-04-0341.
Ref 19 Regulation of host gene expression by HIV-1 TAR microRNAs. Retrovirology. 2013; 10: 86.
Ref 20 The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. doi: 10.1093/nar/28.1.235.
Ref 21 Discovery and optimization of chromenotriazolopyrimidines as potent inhibitors of the mouse double minute 2-tumor protein 53 protein-protein interaction. J Med Chem. 2009 Nov 26;52(22):7044-53. doi: 10.1021/jm900681h.
Ref 22 Small-molecule inhibitors of the MDM2-p53 protein-protein interaction based on an isoindolinone scaffold. J Med Chem. 2006 Oct 19;49(21):6209-21. doi: 10.1021/jm0601194.
Ref 23 TTD: Therapeutic Target Database describing target druggability information. Nucleic Acids Res. 2024 Jan 5;52(D1):D1465-D1477. doi: 10.1093/nar/gkad751.
Ref 24 A phase I pharmacokinetic and pharmacodynamic study of CHR-3996, an oral class I selective histone deacetylase inhibitor in refractory solid tumors. Clin Cancer Res. 2012 May 1;18(9):2687-94. doi: 10.1158/1078-0432.CCR-11-3165.
Ref 25 HDAC inhibitors: a 2013-2017 patent survey. Expert Opin Ther Pat. 2018 Apr 19:1-17. doi: 10.1080/13543776.2018.1459568. Online ahead of print.
Ref 26 Omega-alkoxy analogues of SAHA (vorinostat) as inhibitors of HDAC: a study of chain-length and stereochemical dependence. Bioorg Med Chem Lett. 2007 Nov 15;17(22):6261-5. doi: 10.1016/j.bmcl.2007.09.014. Epub 2007 Sep 8.
Ref 27 Exploration of the HDAC2 foot pocket: Synthesis and SAR of substituted N-(2-aminophenyl)benzamides. Bioorg Med Chem Lett. 2010 May 15;20(10):3142-5. doi: 10.1016/j.bmcl.2010.03.091. Epub 2010 Mar 30.
Ref 28 Design, synthesis, and evaluation of biphenyl-4-yl-acrylohydroxamic acid derivatives as histone deacetylase (HDAC) inhibitors. Eur J Med Chem. 2009 May;44(5):1900-12. doi: 10.1016/j.ejmech.2008.11.005. Epub 2008 Nov 19.
Ref 29 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2616).
Ref 30 Novel aminophenyl benzamide-type histone deacetylase inhibitors with enhanced potency and selectivity. J Med Chem. 2007 Nov 15;50(23):5543-6. doi: 10.1021/jm701079h. Epub 2007 Oct 17.
Ref 31 A novel series of histone deacetylase inhibitors incorporating hetero aromatic ring systems as connection units. Bioorg Med Chem Lett. 2003 Nov 3;13(21):3817-20. doi: 10.1016/j.bmcl.2003.07.012.
Ref 32 Alpha-keto amides as inhibitors of histone deacetylase. Bioorg Med Chem Lett. 2003 Oct 6;13(19):3331-5. doi: 10.1016/s0960-894x(03)00685-1.
Ref 33 Trifluoromethyl ketones as inhibitors of histone deacetylase. Bioorg Med Chem Lett. 2002 Dec 2;12(23):3443-7. doi: 10.1016/s0960-894x(02)00754-0.
Ref 34 SAR profiles of spirocyclic nicotinamide derived selective HDAC1/HDAC2 inhibitors (SHI-1:2). Bioorg Med Chem Lett. 2008 Dec 1;18(23):6104-9. doi: 10.1016/j.bmcl.2008.10.052. Epub 2008 Oct 14.
Ref 35 Santacruzamate A, a potent and selective histone deacetylase inhibitor from the Panamanian marine cyanobacterium cf. Symploca sp. J Nat Prod. 2013 Nov 22;76(11):2026-33. doi: 10.1021/np400198r. Epub 2013 Oct 28.
Ref 36 Chemical phylogenetics of histone deacetylases. Nat Chem Biol. 2010 Mar;6(3):238-243. doi: 10.1038/nchembio.313. Epub 2010 Feb 7.
Ref 37 Histone deacetylase inhibitors. J Med Chem. 2003 Nov 20;46(24):5097-116. doi: 10.1021/jm0303094.
Ref 38 Structure-activity relationships on phenylalanine-containing inhibitors of histone deacetylase: in vitro enzyme inhibition, induction of differentiation, and inhibition of proliferation in Friend leukemic cells. J Med Chem. 2002 Jul 18;45(15):3296-309. doi: 10.1021/jm0208119.
Ref 39 N-Hydroxy-(4-oxime)-cinnamide: a versatile scaffold for the synthesis of novel histone deacetylase [correction of deacetilase] (HDAC) inhibitors. Bioorg Med Chem Lett. 2009 Apr 15;19(8):2346-9. doi: 10.1016/j.bmcl.2009.02.029. Epub 2009 Feb 12.
Ref 40 Novel inhibitors of human histone deacetylases: design, synthesis, enzyme inhibition, and cancer cell growth inhibition of SAHA-based non-hydroxamates. J Med Chem. 2005 Feb 24;48(4):1019-32. doi: 10.1021/jm049207j.
Ref 41 Aromatic sulfide inhibitors of histone deacetylase based on arylsulfinyl-2,4-hexadienoic acid hydroxyamides. J Med Chem. 2006 Jan 26;49(2):800-5. doi: 10.1021/jm051010j.
Ref 42 Mercaptoamide-based non-hydroxamic acid type histone deacetylase inhibitors. Bioorg Med Chem Lett. 2005 Apr 15;15(8):1969-72. doi: 10.1016/j.bmcl.2005.02.075.
Ref 43 Structure-based optimization of phenylbutyrate-derived histone deacetylase inhibitors. J Med Chem. 2005 Aug 25;48(17):5530-5. doi: 10.1021/jm0503749.
Ref 44 Zn2+-chelating motif-tethered short-chain fatty acids as a novel class of histone deacetylase inhibitors. J Med Chem. 2004 Jan 15;47(2):467-74. doi: 10.1021/jm0303655.
Ref 45 Heterocyclic ketones as inhibitors of histone deacetylase. Bioorg Med Chem Lett. 2003 Nov 17;13(22):3909-13. doi: 10.1016/j.bmcl.2003.09.007.
Ref 46 Inhibitors of human histone deacetylase: synthesis and enzyme and cellular activity of straight chain hydroxamates. J Med Chem. 2002 Feb 14;45(4):753-7. doi: 10.1021/jm015568c.
Ref 47 New sulfurated derivatives of valproic acid with enhanced histone deacetylase inhibitory activity. Bioorg Med Chem Lett. 2008 Mar 15;18(6):1893-7. doi: 10.1016/j.bmcl.2008.02.007. Epub 2008 Feb 8.
Ref 48 Three new cyclostellettamines, which inhibit histone deacetylase, from a marine sponge of the genus Xestospongia. Bioorg Med Chem Lett. 2004 May 17;14(10):2617-20. doi: 10.1016/j.bmcl.2004.02.062.
Ref 49 Design, synthesis and preliminary biological evaluation of N-hydroxy-4-(3-phenylpropanamido)benzamide (HPPB) derivatives as novel histone deacetylase inhibitors. Eur J Med Chem. 2009 Nov;44(11):4470-6. doi: 10.1016/j.ejmech.2009.06.010. Epub 2009 Jun 17.
Ref 50 Stereodefined and polyunsaturated inhibitors of histone deacetylase based on (2E,4E)-5-arylpenta-2,4-dienoic acid hydroxyamides. Bioorg Med Chem Lett. 2004 May 17;14(10):2477-81. doi: 10.1016/j.bmcl.2004.03.012.
Ref 51 Development of Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Signaling Pathway.J Med Chem. 2019 Feb 28;62(4):1715-1730.
Ref 52 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
Ref 53 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5891).
Ref 54 ClinicalTrials.gov (NCT00130728) A Study to Evaluate the Efficacy of Bevacizumab in Combination With Tarceva for Advanced Non-Small Cell Lung Cancer
Ref 55 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
Ref 56 ClinicalTrials.gov (NCT02198274) Intravenous BIBH 1 in Patients With Metastatic Colorectal Cancer. U.S. National Institutes of Health.
Ref 57 ClinicalTrials.gov (NCT03547999) A Trial of Perioperative CV301 Vaccination in Combination With Nivolumab and Systemic Chemotherapy for Metastatic CRC. U.S. National Institutes of Health.
Ref 58 ClinicalTrials.gov (NCT02152137) Efatutazone With Paclitaxel Versus Paclitaxel Alone in Treating Patients With Advanced Anaplastic Thyroid Cancer. U.S. National Institutes of Health.
Ref 59 ClinicalTrials.gov (NCT00087165) GTI-2040, Docetaxel, and Prednisone in Treating Patients With Prostate Cancer. U.S. National Institutes of Health.
Ref 60 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
Ref 61 ClinicalTrials.gov (NCT01036113) A Phase 2 Study of EZN-2208 in Patients With Metastatic Breast Cancer. U.S. National Institutes of Health.
Ref 62 ClinicalTrials.gov (NCT00909740) A Study of the Safety and Pharmacokinetics of MEGF0444A Administered to Patients With Advanced Solid Tumors. U.S. National Institutes of Health.
Ref 63 VC-01's Path to the Clinic. Viacyte. 2015.
Ref 64 ClinicalTrials.gov (NCT04660812) An Open Label Study Evaluating the Efficacy and Safety of AB928 Based Treatment Combinations in Patients With Metastatic Colorectal Cancer.. U.S. National Institutes of Health.
Ref 65 ClinicalTrials.gov (NCT02726334) A Phase I, Dose Escalation Study of BNC101 in Patients With Metastatic Colorectal Cancer.. U.S. National Institutes of Health.
Ref 66 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800029052)
Ref 67 Clinical pipeline report, company report or official report of Genentech (2011).
Ref 68 Phase II Study of Saracatinib (AZD0530) in Patients With Previously Treated Metastatic Colorectal Cancer. Invest New Drugs. 2015 Aug;33(4):977-84.
Ref 69 Design and development of antisense drugs. Expert Opin. Drug Discov. 2008 3(10):1189-1207.